SUMATHI SIVAPALASINGAM, senior medical director at Regeneron, the New York–based biotech, has spent recent weeks, like many Americans, working from home. But even hunkered down in her Brooklyn apartment, Sivapalasingam, an infectious disease specialist and physician who previously worked at Bellevue Hospital and battled outbreaks around the world for the CDC, has felt very much in the thick of the fight against COVID-19.
When Fortune spoke with her in early April, she was spending nearly every waking moment on the phone, speaking with clinical trial investigators and physicians about Kevzara, a rheumatoid arthritis drug developed by Regeneron and Sanofi, the French pharmaceutical firm, that is being studied as a possible treatment for the most critically ill COVID-19 patients. The companies are actively testing the drug—an immune signal blocker that…